Contact:
| David K. Waldman/John W. Heilshorn |
The Quigley Corporation |
| Lippert Heilshorn & Associates |
Carl Fonash |
| (212) 838-3777 |
Shareholder Relations |
| dwaldman@lhai.com |
(267) 880-1111 |
Quigley Pharma Appoints Two New Members to its Scientific Advisory Board
DOYLESTOWN, PA. - December 20, 2004 - The Quigley Corporation (Nasdaq: QGLY)
today announced that doctors Mark Lebwohl and Phillip A. Low have been
appointed to the scientific advisory board of Quigley Pharma, Inc.
Mark Lebwohl, MD, is a professor of dermatology and is the current chairman of
the department of dermatology at Mount Sinai School of Medicine in New York
City. Dr. Lebwohl is an opinion leader in psoriasis and related disorders.
Phillip A. Low, M.B., B.S. (Syd.), M.D. (Syd.), F.R.A.C.P., FRCP, is the
chairman of the division of clinical neurophysiology at The Mayo Clinic in
Rochester, Minnesota. Dr. Low serves on the editorial board of numerous
publications including Muscle & Nerve, Journal of the Autonomic Nervous
System, Journal of Clinical Neurophysiology and Journal of Clinical
Neuromuscular Diseases. He serves on the scientific advisory board of the
Neuropathy Association and is a member of the steering committee--NIDDK/NHLBI
Animal Models of Diabetic Complications Neuropathy Disease Validation
Committee. Dr. Low is a co-author of The Textbook of Diabetic Neuropathy.
Continuing Members of the Scientific Advisory Board are:
- Nicholas Diamond, D.O. of the Diamond Pain Clinic, Elkins Park, Pennsylvania.
Dr. Diamond is a researcher in pain and rehabilitation and an editorial board
member of the American Journal of Pain Management;
- Mario Guralnik, Ph.D., president of Synergy Research, Inc, a professional
independent clinical contract research organization specializing in clinical
drug development;
- Edwin Keates, M.D., of Northern Ophthalmic Associates, Inc., Jenkintown,
Pennsylvania. Dr. Keates' research has been presented at the American Academy
of Neurology and published in the Johns Hopkins Medical School journal Advanced
Studies in Medicine;
- Peter Lodewick, M.D. of Lodewick Diabetes Center, Birmingham, Alabama. Dr.
Lodewick, a diabetic research scientist and author of several books on
diabetes;
- Philip Raskin, M.D., Professor of Medicine, Department of Internal Medicine,
University of Texas, Southwestern Medical Center at Dallas, Texas. Dr. Raskin
serves as the editor of the Journal of Diabetes Complications and Director of
the University of Diabetes Treatment Center/Parkland Memorial Hospital, Dallas,
Texas.
At the December 3 meeting of the scientific advisory board, all data from the
past year's studies were presented and discussed.The keynote presentation by
Professor John Oxford and Dr. Robert Lambkin of Retroscreen Virology Limited,
Bartholomew's and the Royal London Hospital, Queen Mary's School of Medicine
and Dentistry, London, was presented remotely from London, England. They
presented invitro data on the virucidal and virustatic activitiy of QR-441 on
the Avian Flu Virus and its implications.
Professor Oxford stated that the unique compound QR-435, with broad-spectrum
anti-viral activity, has the potential to be stockpiled for use in an influenza
pandemic or homeland security scenario.
The Quigley Corporation (Nasdaq: QGLY, http://www.Quigleyco.com) is a leading
developer and marketer of diversified health products including the COLD-EEZE®
family of patented zinc gluconate glycine (ZIGG™) lozenges and sugar free
tablets. In September of 2004, The Company has also formed a wholly owned
subsidiary, Quigley Manufacturing, Inc. with the acquisition of two FDA
approved facilities to manufacture its COLD- EEZE® branded lozenges.
InnerLight, Inc., a wholly owned subsidiary, was formed in January 2001 for the
purpose of introducing new products to the marketplace through a network of
independent distributors. In addition to Over-The-Counter (OTC) products, the
Company has formed Quigley Pharma Inc. (http://www.QuigleyPharma.com), a
wholly owned ethical pharmaceutical subsidiary, to introduce a line of
naturally derived patented prescription drugs. The Quigley Corporation's
customers include leading national wholesalers and distributors, as well as
independent and chain food, drug and mass merchandise stores and pharmacies.
The Quigley Corporation makes no representation that the U.S. Food and Drug
Administration or any other regulatory agency will grant an IND or take any
other action to allow the aforementioned products to be studied or marketed.
Furthermore, no claim is made that the potential medicine discussed here is
safe, effective, or approved by the Food and Drug Administration.
Certain statements in this press release are "forward-looking statements"
within the meaning of the Private Securities Litigation Reform Act of 1995 and
involve known and unknown risk, uncertainties and other factors that may cause
the company's actual performance or achievements to be materially different
from the results, performance or achievements expressed or implied by the
forward-looking statement. Factors that impact such forward-looking statements
include, among others, changes in worldwide general economic conditions,
changes in interest rates, government regulations, and worldwide competition.
|
 |
